Moderna (NASDAQ:MRNA) Lowered to Neutral Rating by The Goldman Sachs Group

The Goldman Sachs Group lowered shares of Moderna (NASDAQ:MRNA) from a buy rating to a neutral rating in a research report report published on Wednesday morning, MarketBeat Ratings reports. They currently have $51.00 price objective on the stock, down from their previous price objective of $99.00.

A number of other analysts also recently weighed in on the company. Argus downgraded Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Barclays lowered their price target on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a research note on Friday, November 8th. JPMorgan Chase & Co. reduced their price objective on shares of Moderna from $59.00 to $45.00 and set an “underweight” rating for the company in a research note on Tuesday, November 26th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Friday, November 8th. Finally, Jefferies Financial Group dropped their target price on shares of Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a report on Tuesday, October 15th. Four analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $67.26.

Moderna Price Performance

Shares of MRNA opened at $40.72 on Wednesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. Moderna has a 1 year low of $31.94 and a 1 year high of $170.47. The company’s fifty day moving average is $40.87 and its two-hundred day moving average is $62.03.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. During the same period in the prior year, the company posted ($1.39) earnings per share. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. On average, analysts forecast that Moderna will post -9.27 earnings per share for the current fiscal year.

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders sold 2,664 shares of company stock worth $115,210. Insiders own 15.70% of the company’s stock.

Institutional Investors Weigh In On Moderna

Hedge funds have recently modified their holdings of the stock. Axiom Advisory LLC raised its stake in Moderna by 1.6% during the third quarter. Axiom Advisory LLC now owns 12,672 shares of the company’s stock worth $847,000 after purchasing an additional 198 shares during the period. Arkadios Wealth Advisors increased its holdings in shares of Moderna by 2.2% during the 3rd quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company’s stock worth $764,000 after buying an additional 243 shares during the last quarter. Knuff & Co LLC raised its position in shares of Moderna by 5.4% in the 3rd quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock worth $316,000 after buying an additional 244 shares during the period. Stephens Inc. AR grew its position in Moderna by 7.9% during the third quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock valued at $223,000 after acquiring an additional 245 shares during the period. Finally, Mather Group LLC. increased its stake in Moderna by 25.7% during the third quarter. Mather Group LLC. now owns 1,281 shares of the company’s stock worth $86,000 after acquiring an additional 262 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.